In response to the recent news regarding Sarepta/Roche’s Gene Therapy Elevidys™ (delandistrogene moxeparvovec), the EMA have issued a negative opinion on the conditional marketing authorization of Elevidys. This is very unfortunate news for our European families and will add additional complexity to any hope of a Canadian approval. However, the safety of our loved ones is our number one priority and it is important that both the manufacturer and regulators understand the risk/benefit profile better.

You can access Roche’s response to this news by clicking on the link below.

Want to know more about Duchenne Research?

Scientists and medical experts have been tirelessly pursuing diverse approaches to defeat Duchenne muscular dystrophy. From tackling the root cause to alleviating symptoms, the field of research is vast and promising. Explore the various strategies being developed and tested, and gain insights into the future of muscular dystrophy treatment: